Komori
Nagaoka International (6239) · RiskFirst stated

Upfront Investment Risk in Research and Development and Capital Expenditures

First written in FY2016. . Latest entry: FY2016.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Risk of Rising R&D Expenses and Development Investment BurdenA theme 22 companies write about · 23 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2019: 4 of 13 companies on the "Worse" side.

1 other company's latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 22 companies compared. The sentences above are computed from all 22.
Full recordFilings, disclosures and news, newest first
  1. FY2016First statedAnnual report

    「Research and development expenses and related capital investment are incurred upfront through improvements to existing products and the research and development of new products. Accordingly, if product development and other initiatives fail to get on track despite the investment in research and development and capital expenditures, this could affect the Group's operating results and financial position.」

    The Company describes a framework for limiting investment risk through marketing, project management and alliances with other companies.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Nagaoka International yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Upfront Investment Risk in Research and Development and Capital Expenditures | NAGAOKA INTERNATIONAL CORPORATION (6239) | Komori